HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Senior friendly CRP rule

This article was originally published in The Rose Sheet

Executive Summary

Senior friendly CRP rule: Consumer Product Safety Commission staff to forward an analysis to the commission by the end of the month of recent comments on the agency's planned "senior friendly" revisions to the child resistant packaging test protocol. CPSC announced Feb. 21 that it was reopening the comment period ("The Rose Sheet" Feb. 27, p. 5). The commission heard testimony from eight witnesses at a March 16 public hearing, including the Coalition for Responsible Packaging, which represents NDMA, American Home Products, J&J and Perrigo, among others. Comments addressed whether CPSC would exceed its statutory authority by requiring that CRPs be easy for seniors to use properly and whether the commission would improperly address consumer convenience rather than safety with the final rule...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel